LCNEC was divided into two independent subtypes, type I was similar to classic SCLC subtype, characterized by alterations in STK11/KEAP1, neuroendocrine phenotype with high expression of ASCL1 and DLL3, down-regulating NOTCH pathway, while type II was characterized by changes in TP53/RB1 displaying predominantly non-neuroendocrine phenotype, with low expression of CgA and Syn, low expression of ASLC1 and DLL3 alongside activation of NOTCH pathway. This evidence concerns the gene ASCL1 and large cell neuroendocrine carcinoma.